|
ACBD5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.05300004458331E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.50620000097746E-08 |
| Normal-vs-Stage2 |
5.318200E-02 |
| Normal-vs-Stage3 |
7.08019975981244E-10 |
| Normal-vs-Stage4 |
1.88320004035347E-09 |
| Stage1-vs-Stage2 |
1.723800E-02 |
| Stage1-vs-Stage3 |
5.978000E-02 |
| Stage1-vs-Stage4 |
3.923900E-02 |
| Stage2-vs-Stage3 |
1.139210E-03 |
| Stage2-vs-Stage4 |
1.316450E-03 |
| Stage3-vs-Stage4 |
5.618200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6538992397841E-11 |
| Normal-vs-AfricanAmerican |
3.045000E-04 |
| Normal-vs-Asian |
3.56809999990659E-07 |
| Caucasian-vs-AfricanAmerican |
4.558600E-01 |
| Caucasian-vs-Asian |
9.242200E-01 |
| AfricanAmerican-vs-Asian |
5.616600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.2857998240371E-10 |
| Normal-vs-Female |
9.66869995178143E-09 |
| Male-vs-Female |
1.790440E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.82119999969643E-07 |
| Normal-vs-Age(41-60Yrs) |
9.87049997291933E-09 |
| Normal-vs-Age(61-80Yrs) |
3.69180000000524E-05 |
| Normal-vs-Age(81-100Yrs) |
5.368700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.843400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.704800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.099400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.448560E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.710000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.183000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.979700E-03 |
| Classical-VS-Follicular |
4.43269999594875E-08 |
| Classical-VS-Other |
5.197200E-01 |
| Classical-VS-Normal |
1.7537082896979E-12 |
| Tall-VS-Follicular |
2.1528001603599E-10 |
| Tall-VS-Other |
2.310200E-01 |
| Tall-VS-Normal |
4.06563671617732E-13 |
| Follicular-VS-Other |
1.883800E-01 |
| Follicular-VS-Normal |
5.164400E-01 |
| Other-VS-Normal |
2.643900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.14490000002743E-06 |
| Normal-vs-N1 |
4.47741843601079E-12 |
| N0-vs-N1 |
1.237530E-04 |
|
|
